0.0001
0.0000
(0.00%)
At close: January 10 at 3:00:00 PM EST
Key Executives
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Ernest Loumaye M.D., OB/GYN, Ph.D. | Co-Founder & Chairman | 40k | -- | 1952 |
| Mr. Fabien Lefebvre de Ladonchamps | CEO & Director | -- | -- | 1979 |
| Ms. Delphine Renaud | Personal Assistant to the CSO and Head of R&D | -- | -- | -- |
ObsEva SA
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 15
Description
ObsEva SA, a biopharmaceutical company, focuses on the development of novel therapies to improve women's reproductive health. It develops Nolasiban, an oral oxytocin receptor agonist for improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.
Corporate Governance
ObsEva SA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
April 26, 2023 at 12:00 AM UTC
15-12G: Notice of termination of registration of a class of securities under Section 12(g)
March 27, 2023 at 12:00 AM UTC
25: Notification filed by issuer to voluntarily withdraw a class of securities from listing and registration on a national securities exchange
Related Tickers
IDIA.SW Idorsia Ltd
0.7790
-1.77%
SANN.SW Santhera Pharmaceuticals Holding AG
13.68
-2.84%
EVGN Evogene Ltd.
1.5700
-4.27%
KALA KALA BIO, Inc.
6.81
-0.15%
IMVT Immunovant, Inc.
23.48
-0.63%
CGON CG Oncology, Inc.
30.20
-0.85%
ADAP Adaptimmune Therapeutics plc
0.6200
+0.02%
CLLS Cellectis S.A.
1.8500
-4.15%
ARQT Arcutis Biotherapeutics, Inc.
13.81
-9.56%
APLS Apellis Pharmaceuticals, Inc.
27.44
-16.85%